menu
    • menu
    [{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Urology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Galderma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2023","type":"Termination","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Galderma"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Allergan Aesthetics","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Allergan Aesthetics"},{"orgOrder":0,"company":"Ipsen","sponsor":"Galderma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"\nSNAP25||ACh receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"ACh receptor||Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IPN59011","moa":"ACh-alpha-1\/beta-1\/delta\/gamma receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Clementia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"IPN60130","moa":"ALK-2 receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Merrimack Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Merrimack Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Merrimack Pharmaceuticals"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Merrimack Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Irinotecan Hydrochloride","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":1.03,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"IRLAB","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mesdopetam","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ IRLAB","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ IRLAB"},{"orgOrder":0,"company":"Ipsen","sponsor":"IRLAB","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Mesdopetam","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ IRLAB","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ IRLAB"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IPN01194","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IPN60090","moa":"||Glutaminase-1","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"9","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection, Prolonged Release","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Triptorelin Pamoate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Epizyme","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Epizyme","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ritivixibat","moa":"IBAT","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Elobixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Elobixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Elobixibat","moa":"Ileal bile acid transporter","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Albireo Pharma \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Hercules Capital"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jadeite Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Albireo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Albireo Pharma"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Albireo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Albireo Pharma"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Albireo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0.94999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jadeite Medicines","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Jadeite Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Jadeite Medicines"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Divestment","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Jefferies"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Genpharm","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Genpharm"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Albireo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0.94999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.94999999999999996,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Sagard Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Sagard Healthcare Partners","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Sagard Healthcare Partners"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Albireo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Mecasermin","moa":"Insulin-like growth factor I receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Ipsen","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"Mecasermin","moa":"Insulin-like growth factor I receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Ipsen","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"225-Ac","moa":"||Neurotensin type-1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0.57999999999999996,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.57999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Fusion Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Fusion Pharma"},{"orgOrder":0,"company":"Ipsen","sponsor":"Fusion Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FPI-2059","moa":"Neurotensin type-1 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"5","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Genfit","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0.54000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.54000000000000004,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Genfit","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Elafibranor","moa":"||Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0.54000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0.54000000000000004,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Genfit","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Genfit","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Genfit"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Elafibranor","moa":"Peroxisome proliferator-activated receptor delta | Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"IPN01195","moa":"RAF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Day One Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Tovorafenib","moa":"RAF serine\/threonine protein kinase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0.46000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.46000000000000002,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Clementia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palovarotene","moa":"Retinoic acid receptor gamma","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"IPN10200","moa":"SNAP-25","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IPN10200","moa":"SNAP-25","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"IPN10200","moa":"SNAP-25","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"IPN10200","moa":"SNAP-25","graph1":"Neurology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 2 | Somatostatin receptor 5","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Phillips - Medisize","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Financing","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 2 | Somatostatin receptor 5","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Phillips - Medisize","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Phillips - Medisize"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 2 | Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Lanreotide Acetate","moa":"Somatostatin receptor 5","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"111-In IPN01087","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Marengo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Partnership","leadProduct":"Invikafusp Alpha","moa":"T-cell-5-beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ipsen","amount2":1.5900000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.5900000000000001,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"7","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"BAKX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"BKX-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0.84999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.84999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Biomunex Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"BMX-502","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0.60999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.60999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"FS001","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":1.03,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"STRO-003","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Bristol Myers Squibb","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Exelixis","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Exelixis"},{"orgOrder":0,"company":"Ipsen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Undisclosed"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"||Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase III","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"10","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"1","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exicure","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Ipsen","amount2":1.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":1.02,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"University Of Montreal","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ University Of Montreal","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ University Of Montreal"},{"orgOrder":0,"company":"Ipsen","sponsor":"Exicure","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"IRELAND","productType":"Undisclosed","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Ipsen","amount2":1.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":1.02,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Marengo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Ipsen","amount2":1.2,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Accent Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ipsen","amount2":0.45000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Ipsen \/ Ipsen"},{"orgOrder":0,"company":"Ipsen","sponsor":"Skyhawk Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"Ipsen","amount2":1.8,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":1.8,"dosageForm":"Undisclosed","sponsorNew":"Ipsen \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Ipsen \/ Ipsen"}]

    Find Clinical Drug Pipeline Developments & Deals by Ipsen

    Menu

    Ipsen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IPN10200

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

                            Details : IPN10200 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Torticollis.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 22, 2025

                            Lead Product(s) : IPN10200

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Recipient : Gustave Roussy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

                            Details : Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 18, 2025

                            Lead Product(s) : Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Recipient : Gustave Roussy

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Palovarotene

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy A...

                            Details : Palovarotene is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 03, 2025

                            Lead Product(s) : Palovarotene

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IPN01195

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

                            Details : IPN01195 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 18, 2025

                            Lead Product(s) : IPN01195

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tazemetostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : University of Utah

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indo...

                            Details : Tazemetostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 13, 2025

                            Lead Product(s) : Tazemetostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : University of Utah

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mecasermin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

                            Details : Through the acquisition, Eton’s bolsters its pediatric endocrinology with the addition of Increlex (mecasermin). It is used to treat pediatric patients 2 years of age and older who suffer from SPIGFD.

                            Product Name : Increlex

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            December 20, 2024

                            Lead Product(s) : Mecasermin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tazemetostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Eric Jacobsen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tazemetostat Plus CHOP in 1L T-cell Lymphoma

                            Details : Tazemetostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 18, 2024

                            Lead Product(s) : Tazemetostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Eric Jacobsen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mecasermin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

                            Details : Eton will acquire Increlex (mecasermin injection) from Ipsen, which is indicated for treating patients suffering from SPIGFD because their bodies do not make enough IGF-1.

                            Product Name : Increlex

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            October 03, 2024

                            Lead Product(s) : Mecasermin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IPN10200

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

                            Details : IPN10200 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Migraine Disorders.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 03, 2024

                            Lead Product(s) : IPN10200

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed

                            Ipsen

                            France arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Odevixibat

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ipsen’s Kayfanda® Approved in EU for Cholestatic Pruritus in Alagille Syndrome

                            Details : Kayfanda (odevixibat) is a once-daily non-systemic IBAT inhibitor, being evaluated for the treatment of cholestatic pruritus in Alagille Syndrome in patients aged 6 months or older.

                            Product Name : Bylvay

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 23, 2024

                            Lead Product(s) : Odevixibat

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth